Bryan J. Schneider
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Bryan J. Schneider

Oncology | Hematology | Hematology Oncology
Regents Of The University Of Michigan
1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Experienced in WT1-Related Wilms Tumor Syndromes
Regents Of The University Of Michigan
1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bryan Schneider is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Schneider is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Schneider is currently accepting new patients.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
University Of Michigan Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr, Suite 0331, Ann Arbor, MI 48109
Other Locations
REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Ctr Dr, Ann Arbor, MI 48109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Other
Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples
Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Other
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples
Enrollment Status: Recruiting
Publish Date: June 29, 2025
Intervention Type: Other
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
Enrollment Status: Terminated
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Capecitabine, Talazoparib, Atezolizumab, Inavolisib
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients With Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen
A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients With Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen
Enrollment Status: Terminated
Publish Date: August 26, 2019
Intervention Type: Other
Study Phase: Not Applicable
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
Enrollment Status: Completed
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

73 Total Publications

Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action.
Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action.
Journal: JCO oncology practice
Published: February 20, 2025
Similar Doctors
Ajjai S. Alva
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ajjai S. Alva
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ajjai S. Alva
Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (0.1 miles away)
734-936-5738
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Ajjai Alva is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Alva is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Lymphadenectomy, and Nephrectomy. Dr. Alva is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sheela Tejwani
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sheela Tejwani
Oncology | Hematology

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (33.6 miles away)
313-916-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sheela Tejwani is an Oncologist and a Hematologist in Detroit, Michigan. Dr. Tejwani is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Adult Soft Tissue Sarcoma, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration. Dr. Tejwani is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ulka N. Vaishampayan
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ulka N. Vaishampayan
Oncology

Regents Of The University Of Michigan

39901 Traditions Dr, 
Northville, MI 
 (17.8 miles away)
888-287-1082
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ulka Vaishampayan is an Oncologist in Northville, Michigan. Dr. Vaishampayan is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schneider's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile